Volume 20, Number 1—January 2014
Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan
||Children <5 y of age, calibration to 2009 sentinel data
|Mean duration of protection, mo||Coverage||Efficacy against severe RVGE||Efficacy against mild RVGE||Deaths||Hospital admissions||Outpatient clinic visits*||Homecare episodes*|
|Base case, low||12||0.9||0.74||0.51||63||3,740||0.6||0.5Im|
|Base case, high||12||0.9||0.86||0.64||74||4,274||1.4||1.5Im|
|Scenario A, low||12||0.89||0.74||0.51||63||3,740||0.6||0.5Im|
|Scenario A, high||12||0.89||0.86||0.64||74||4,274||1.4(||1.5Im|
|Scenario B, low||12||1.0||0.74||0.51||63||3,740||0.6||0.5Im|
|Scenario B, high||12||1.0||0.86||0.64||74||4,274||1.4||1.5Im|
|Scenario C, low||24||0.9||0.74||0.51||63||3,740||0.6||0.5Im|
|Scenario C, high||24||0.9||0.86||0.64||74||4,274||1.4||1.5Im|
*RVGE, rotavirus gastroenteritis; Is, modeled incidence of severe RVGE; Ih, modeled incidence of hospital admissions; Im, modeled incidence of mild RVGE.
†The numbers of outpatient clinic and homecare visits were not calibrated.
Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.